Immunogenicity and safety of quadrivalent influenza vaccine among young and older adults in Tianjin, China: implication of immunosenescence as a risk factor

Table 6 AEs in young and older adult groups

AE, n (%)	< 65 years (n = 79)	≥ 65 years (n = 88)	P
Participants with AEs	18 (22.78)	14 (15.91)	0.260
Participants with local AE	11 (13.92)	8 (9.09)	0.326
Participants with systemic AE	10 (12.66)	7 (7.95)	0.316
Total AE	30(40.0)	21(23.9)
Immediate unsolicited AE	0 (0.00)	1 (1.14)
Unsolicited AE	2 (2.53)	0 (0.00)
Solicited AE	28(35.4)	20(22.7)
Local AE	15(19.0)	11(12.5)
Redness	3 (3.80)	2 (2.27)
Swelling	1 (1.27)	2 (2.27)
Pain	8 (10.13)	5 (5.68)
Rash	1 (1.27)	0 (0.00)
Itch	2 (2.53)	1 (1.14)
Induration	0 (0.00)	1 (1.14)
Systemic AE	15(19.0)	10(11.4)
Fever	5 (6.33)	4 (4.55)
Myalgia	4 (5.06)	1 (1.14)
Fatigue	3 (3.80)	3 (3.41)
Headache	2 (2.53)	1 (1.14)
Cough	0 (0.00)	1 (1.14)
Nausea & Vomiting	1 (1.27)	0 (0.00)
SAE	0 (0.00)	0 (0.00)
MAE	0 (0.00)	0 (0.00)

Abbreviations: AE Adverse event, SAE Serious adverse event, MAE Medically attended event. Comparisons of AEs between the two age groups were performed by Chi-square test

ISSN: 1742-4933